
    
      RIC regimen was given for low and intermediate MDS patients who would receive haplo-HSCT. The
      primary end point was transplant-related mortality. The secondary end points were overall
      survival, disease-free survival, relapse, , graft-versus-host disease (GVHD), and infections.
      Following time is 1 years.
    
  